Formulation for intranasal administration
November 14, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3652589 Use of eucalyptol for enhancing skin permeation of bio-affecting agents Method of administering narcotic antagonists and analgesics and novel dosage forms containing same Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same Nasal delivery of caffeine Method of treatment for allergic rhinitis Method of administering a narcotic analgesic and dosage forms therefor Pyroglutamic acid esters used as dermal penetration enhancers for drugs InventorsAssigneeApplicationNo. 557279 filed on 11/14/1995US Classes:514/646Benzene ring containingExaminersPrimary: MacMillan, Keith D.Attorney, Agent or FirmForeign Patent References
International ClassA61K 031/135AbstractA dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Other References
Field of SearchBenzene ring containing | |
